Unveiling ayahuasca psychopharmacology: the accomplishments of Jordi Riba (1968-2020)
Brazilian Journal of Psychiatry October 7, 2020 Rafael G. Dos Santos, Dráulio Barros de Araújo, Rafael Faria Sanches et al. 2 citations
Editorial
Rafael Faria Sanches
9 papers in the library · 2,277 citations · publishing 2010-2020
Papers
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Psychological Medicine June 15, 2018 Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al. 827 citations
Abstract Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either...
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
Archives of Clinical Psychiatry (São Paulo) February 1, 2018 Rafael G. Dos Santos, Rafael Faria Sanches, Flávia de Lima Osório et al. 37 citations
Abstract Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects....
A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression
bioRxiv (Cold Spring Harbor Laboratory) January 27, 2017 Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al. 22 citations preprint
Abstract Recent open label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. In order to further test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either...
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
Journal of Psychoactive Drugs May 26, 2016 Amanda Amorin Nunes, Rafael G. Dos Santos, Flávia de Lima Osório et al. 92 citations
Recently, the anti-addictive potential of ayahuasca, a dimethyltryptamine(DMT)- and β-carboline-rich hallucinogenic beverage traditionally used by indigenous groups of the Northwest Amazon and currently by syncretic churches worldwide, has received increased attention. To better evaluate this topic, we performed a systematic literature review using the PubMed database to find quantitative...
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression
Journal of Clinical Psychopharmacology December 11, 2015 Rafael Faria Sanches, Flávia de Lima Osório, Rafael G. Dos Santos et al. 468 citations
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in...
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
Brazilian Journal of Psychiatry March 1, 2015 Flávia de Lima Osório, Rafael Faria Sanches, Ligia Ribeiro Horta de Macedo et al. 486 citations
These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.
Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
European Neuropsychopharmacology January 16, 2015 José Carlos Bouso, Fernanda Palhano-Fontes, Antoni Rodrı́guez-fornells et al. 221 citations
Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception, emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that...
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Brazilian Journal of Psychiatry March 1, 2010 Jaime E. C. Hallak, João Paulo Machado‐de‐Sousa, José Alexandre S. Crippa et al. 122 citations
OBJECTIVE: The last decade has seen increasing evidence of dysfunctions in the endogenous cannabinoid system in schizophrenia and of its relationship with the typical cognitive impairment of the disorder. Studies in animal models, healthy volunteers, and psychotic patients clearly suggest an antipsychotic-like effect of cannabidiol. This study investigated the effects of cannabidiol on...